Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
ACG, an integrated pharmaceutical and nutraceutical manufacturing company, will launch a process lab in Germany in 2023.
read more
The growing obese population is predicted to boost demand for weight loss supplements as these are widely adopted by individuals as healthy options to reduce weight. For instance, according to the World Health Organization (WHO), over 1 billion people globally are obese currently (2022).
read more
Alpha Cognition, a biopharmaceutical company, announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).
read more
The global medical marijuana market size was valued at $11.70B in 2021 and is likely to reach value of $40.02B by 2028; it is estimated to grow at a CAGR of 19.2% from 2022 to 2028, according to a report by The Insight Partners.
read more
Global dietary supplements market will project a CAGR of 8.72% for the forecast period of 2022-2029, according to a study by Data Bridge Market Research.
read more
Tris Pharma announced the decision by the US District Court for the District of New Jersey to uphold the validity of various patents relating to QuilliChew ER® (methylphenidate hydrochloride) extended-release chewable tablets, for oral use.
read more
Novadoz Pharmaceuticals will manufacture several new products, including:
Pirfenidone 267 mg and 801 mg tablets (AB rated to Esbriet),
Chlorpromazine 25 mg, 50 mg, 100 mg and 200 mg tablets (AB rated to Thorazine)
Bortezomib 3.5 mg vials (AP rated to Velcade)
Bumetanide 4 mL SDV and 10 mL MDV (0.25 mg/mL) (AP rated to Bumex)
read more
The global herbal medicine market size was worth around $166B in 2021 and is predicted to grow to around $348B by 2028 with a compound annual growth rate (CAGR) of roughly 11.2% between 2022 and 2028, according to a Zion Market Research study.
read more
Tris Pharma announced that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII are now available in pharmacies. DYANAVEL XR was approved by the U.S. Food and Drug Administration for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.
read more
The potential growth difference for the nutritional supplements market between 2020 and 2025 is $27.67B, as per the latest market analysis report by Technavio. The report predicts the market to witness an accelerating growth momentum at a CAGR of 4%.
read more
Lumicera Health Services announced that it will be offering abiraterone acetate 250 mg tablets – the first generic drug made by CivicaScript™.
read more
The increased number of generic versions of several key medications being launched in strong areas such as the United States is driving the global prescription drugs market, according to a report by Data Bridge Market Research. Its market analysis says the global market was valued at $1,015.63B in 2021 and is expected to reach $1,482.35B by 2029, ...
read more
The nutricosmetics market value is poised to cross $13.7B by 2030, according to a new research report by Global Market Insights. The nutricosmetics Industry is anticipated to register 8.1% CAGR between 2022 and 2030 due to increasing hair and skin care problems and rising awareness of health management.
read more
Catalent announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty contract development and manufacturing organization (CDMO) with a facility in Greenville, North Carolina, for $475M from Mayne Pharma Group Limited.
read more
JAMP Pharma Corporation is voluntarily, on a precautionary basis, recalling one product lot of Atorvastatin tablets, 40 mg, 500-format (lot MHC1403A) to the retail level (type 1 recall).
read more